Most dangerous prescription drugs - Statins

Have you check your latest total cholesterol levels? If it's above 5.0 mmol/l or 193mg/dl, you doctor will tell you to go on statin drugs, @ cholesterol lowering drugs. Rings a bell? In USA, before year 2004, total cholesterol levels of 130mg/dl is still considered healthy. Now, according to USA government (National Cholesterol Education Program panel) updated guidelines, it is recommended that your total cholesterol levels is below 100mg/dl or 2.586 mmol/l!! This sounds like everyone is going to be on statin drugs soon! How many people do you know is on cholesterol lowering drugs? Is your dad or mum on this so called 'heart disease prevention' pill? I think the million dollar question is, how much truth do you know about cholesterol, statins and heart disease. 

All my life, me myself, believed that cholesterol is bad and causes heart disease. No, I'm not joking, and most of the foods I eat, is low is fat and cholesterol. I didn't know, I was partially ignorant, and followed the health medias and doctors advise. Well, I'm not the only one, I'm not alone, and majority of population, I would say more then 99.99999% of people, is still having the same mindset of what I've been through years ago, or what it's been called "The Great Cholesterol Cover Up". 

If you have read my earlier posts about "High Cholesterol Causes Heart Diseases?", you will get to know much more about cholesterol, saturated fats, and heart disease. Does any of you know why we are all stucked and hardwired to this mindset that cholesterol causes heart disease? It's simple, there could be 29 billions reasons why and this new documentary will reveal the truth about the great cholesterol cover up! Who should watch this documentary? Everyone! And I mean every adult above 18 years old, especially the ones who are taking cholesterol lowering drugs. For medical professionals or doctors, you may want to lower your ego first, and watch it with an open mind, use some common sense and do your own research, and I mean proper in depth research. I know most doctors paycheck if largely based on selling prescription drugs to patients, and cholesterol lowering drugs is one of the most profitable drugs of all drugs sold in the pharmacies, clinics and hospitals. 

Although, there are also many health experts, nutritionists, doctors and scientists agreed that the whole 'cholesterol causes heart disease' is a nonsense health scam,  but more and more people are now taking this highly dangerous drugs which have severe to deadly side effects. In fact, the lipid hypothesis is the biggest health scam ever in the history of mankind. 

I will not elaborate further about cholesterol and heart disease, but feel free to read my previous posts about cholesterol if you are curious to know more truth about the lipid hypothesis. Else, there are tons of books written by multiple authors and doctors available in amazon.com, which revealed the truth about this whole health scam. I hereby present to you below, the link to watch the first 13 mins of the documentary "29 billion reasons to lie about cholesterol" and its official website. Meanwhile, you can visit www.drugs.com, if you want to know the extent of the side effects of any precription drugs. Remember, drugs don't heal, they destroy. This nonsense health scam needs to end, and more people MUST realize and know the truth of this dangerous drug, cholesterol and the cause of heart disease.   

STATIN NATION (First 13 mins)

http://www.youtube.com/watch?v=Ry1Z8buyd8I

http://www.statinnation.net/ (29 billion reasons to lie about cholesterol)

Lipitor Side Effects (http://www.drugs.com/sfx/lipitor-side-effects.html)

** Note: Lipitor is the most profitable statin drug prescribed worldwide. 

Gastrointestinal

Gastrointestinal side effects have been the most commonly reported. These have been reported in less than 4% of patients and have included constipation, flatulence, dyspepsia, and abdominal pain. Diarrhea has been reported in up to 5.3% of patients and may be dose-related. Other gastrointestinal side effects observed with HMG-CoA reductase inhibitors have included pancreatitis, anorexia, and vomiting. Most effects tended to be mild and transient.

Hepatic

In clinical trials, liver enzyme elevations returned to pretreatment levels upon discontinuation or dose reduction of atorvastatin (the active ingredient contained in Lipitor) Nawrocki and colleagues reported elevated bilirubin levels in 2/30 patients and elevated AST and ALT levels in 1/30 patients.

Hepatic side effects including altered liver function have been observed with all HMG-CoA reductase inhibitors. In premarketing clinical trials, up to 0.7% of patients experienced persistent, elevated AST and/or ALT values greater than three times the upper normal limits on two or more occasions. Elevations of liver enzymes may be dose-related. Other hepatic side effects of the HMG-CoA class have included hepatitis, cholestatic jaundice, fatty changes in the liver, cirrhosis, fulminant hepatic necrosis, and liver failure.

Musculoskeletal

HMG-CoA reductase inhibitors (statins) have been associated with rare cases of severe myopathy and rhabdomyolysis, accompanied by increases in creatine kinase, myoglobinuria, proteinuria, and renal failure. Concomitant use with gemfibrozil (fibric acid derivatives), niacin, cyclosporine, erythromycin (macrolides) or azole antifungals may increase the incidence and severity of musculoskeletal side effects. Other variables associated with an increased risk of statin-induced myopathy include, advanced age, small body stature, female gender, renal and/or hepatic dysfunction, perioperative periods, hypothyroidism, diabetes mellitus, and alcoholism. 

A case of atorvastatin-induced early-onset (after 4 doses) rhabdomyolysis has been reported in a patient with nephrotic syndrome. The authors suggest that the patient's underlying renal dysfunction may have predisposed the patient to rhabdomyolysis.

Musculoskeletal side effects have included uncomplicated myalgia and arthralgia. Milder forms of myotoxicity (i.e., myalgia) are commonly reported and occur in approximately 5% to 7% of patients taking a statin drug. Rhabdomyolysis and myopathy related to HMG-CoA reductase inhibitor use have been reported rarely. One case of atorvastatin-induced dermatomyositis has been reported. Tendon rupture has been reported in postmarketing surveillance.

Hematologic

Hematologic side effects including hemolytic anemia, thrombocytopenia, and leukopenia have occurred with HMG-CoA reductase inhibitors. These effects may be manifestations of a hypersensitivity reaction.

Nervous system

Nervous system side effects of headache and weakness have occurred with HMG-CoA reductase inhibitors. In addition, at least one case of polyneuropathy attributed to atorvastatin (the active ingredient contained in Lipitor) use has also been reported. Other nervous system side effects reported with HMG-CoA reductase inhibitors have included dizziness, drowsiness, fatigue, cranial nerve dysfunction, tremor, vertigo, memory loss, decline in cognitive function, paresthesias, peripheral neuropathy, and peripheral nerve palsy.

Renal

Renal side effects including acute renal failure secondary to rhabdomyolysis have been reported with HMG-CoA reductase inhibitors.

Endocrine

Endocrine side effects associated with the use of other HMG-CoA reductase inhibitors have included hypospermia, gynecomastia, and thyroid dysfunction. In addition, acid maltase deficiency (the genetic disorder also referred to as Pompe's Disease) has been revealed following HMG-CoA therapy in at least one presymptomatic patient.

Hypersensitivity

Hypersensitivity reactions have been observed rarely with HMG-CoA reductase inhibitors. Symptoms have included anaphylaxis, angioedema, allergic reaction, urticaria, fever, chills, flushing, malaise and dyspnea. Bullous rashes including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have occurred.

Psychiatric

Psychiatric side effects of HMG-CoA reductase inhibitors have included decreases in libido, anxiety, depression, and insomnia. In addition, nightmares have been associated with atorvastatin (the active ingredient contained in Lipitor) use. Psychiatric side effects reported postmarketing have included cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).

Genitourinary

A 77-year-old female with a history of hypercholesterolemia experienced hemorrhagic cystitis coincident with atorvastatin (the active ingredient contained in Lipitor) therapy. She presented with gross hematuria of approximately 4 weeks duration. She had been given atorvastatin 5 mg daily approximately 1 week before the onset of her hematuria. Urinalysis showed grossly bloody urine with too-numerous-to-count red cells on microscopic examination. Biopsy of the affected areas of the bladder showed congestion of superficial mucosal vessels and mild infiltration of the epithelium and lamina propria with polymorphonuclear leukocytes and lymphocytes, consistent with benign, acute, and chronic inflammatory process. The patient discontinued atorvastatin therapy but continued with her other medication regimen. Her hematuria resolved within 1 week of discontinuing therapy with atorvastatin. At the insistence of her prescriber, she once again was given atorvastatin, with a rapid recurrence of her hematuria. She once again discontinued atorvastatin, and her hematuria rapidly resolved.

Genitourinary adverse effects associated with other HMG-CoA reductase inhibitors have included erectile dysfunction, impotence, and testicular pain. At least one case of hemorrhagic cystitis has been reported.

Dermatologic

Dermatologic reactions have occurred rarely. In premarketing trials, up to 3.8% of patients complained of a rash. Phototoxicity has been associated with atorvastatin (the active ingredient contained in Lipitor) A case of dermatomyositis has also been reported.

Cardiovascular

Analysis of study data has shown an increased risk of hemorrhagic stroke in patients treated with atorvastatin (the active ingredient contained in Lipitor) who had a stroke or TIA within 6 months preceding treatment compared to placebo.

Cardiovascular side effects occurring since market introduction have included angioneurotic edema, peripheral edema, and chest pain. Atorvastatin may also increase the incidence of hemorrhagic stroke in patients with a history of recent stroke or TIA.

Respiratory

Respiratory symptoms reported since market introduction have included bronchitis, rhinitis, pharyngitis, and sinusitis.

Ocular

Ocular side effects including a case of reversible ophthalmoplegia as well as a case of ocular myasthenia have been reported.

A 60-year-old woman with hypercholesterolemia treated with atorvastatin developed painless horizontal diplopia, vertigo, blurry vision, elevated anti-acetylcholine receptor (anti-AchR) antibodies levels, ataxia, and paresthesia of the upper extremities. No other medications were reported. Neurological exam revealed generalized hyperreflexia and finger-nose and gait ataxia. Ptosis was present in both upper eyelids. Discontinuation of atorvastatin resulted in symptom resolution and anti-AchR levels within normal limits.

A 67-year-old women treated for hypercholesterolemia with atorvastatin developed myogenic ptosis and variable incomitant horizontal and vertical strabismus consistent with ocular myasthenia. Following discontinuation of atorvastatin, the patient experienced significant clinical improvement with only mild residual aponeurotic ptosis after 2 months.

Immunologic

Immunologic side effects including a possible case of atorvastatin-induced reversible positive antinuclear antibodies have been reported.

Other

Other side effects reported during clinical trials (in more than 2% of patients) have included infection, accidental injury, flu syndrome, abdominal pain, and back pain. Other side effects reported postmarketing have included anaphylaxis, angioneurotic edema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rhabdomyolysis, fatigue, tendon rupture, fatal and nonfatal hepatic failure, dizziness, depression, peripheral neuropathy, and pancreatitis.

Books references:

The Great Cholesterol Myth: Why Lowering Your Cholesterol Won't Prevent Heart Disease-and the Statin-Free Plan That Will [Paperback]

Jonny Bowden (Author), Stephen Sinatra (Author)

How Statin Drugs Really Lower Cholesterol: And Kill You One Cell at a Time [Paperback]

James B. and Hannah Yoseph (Author)

Statin Drugs Side Effects and the Misguided War on Cholesterol [Paperback]

Duane Graveline (Author)

Lipitor Thief of Memory [Paperback]

Duane Graveline (Author), Kilmer S. McCully (Introduction), Jay S. Cohen (Foreword)

Ignore the Awkward.: How the Cholesterol Myths Are Kept Alive [Paperback]

Uffe Ravnskov (Author)

The Cholesterol Myths: Exposing the Fallacy that Saturated Fat and Cholesterol Cause Heart 

Disease 

Uffe Ravnskov (Author)